ArticleBPC-157cancerangiogenesisVEGF

BPC-157 and the Cancer Question: What the SRS Episode Missed

A Stacked editorial response to Louisa Nicola on Shawn Ryan Show #300 — what the angiogenesis concern gets right, what the framing leaves out, and what the 2025 peer-reviewed literature actually says.

Stacked EditorialMay 4, 20266 min read

Last updated: May 4, 2026.

The Shawn Ryan Show just dropped Episode #300 with neurophysiologist Louisa Nicola, titled "Peptides, Cancer and the Deadly Habits That Lead to Alzheimer's." The episode is already generating the predictable wave of "BPC-157 causes cancer" takes across X, IG, and the podcast-clip ecosystem.

That framing isn't quite what Nicola actually said. And the research is more complete than what made it into the episode.

Both things matter — because incomplete framing on a compound this widely used has its own cost. A cost that doesn't get talked about when the conversation collapses into "is it dangerous, yes or no."

Here's the real picture.

Where Nicola Has a Legitimate Point

Let's be clear up front: the angiogenesis concern is real. It deserves to be taken seriously.

BPC-157 is a potent angiogenic peptide. It works by upregulating VEGF and VEGFR2 — the vascular growth factor receptor pathway implicated in tumor angiogenesis across many solid tumor types. The Akt-eNOS axis it activates promotes new blood vessel formation, which is exactly why it heals tendons, gut lining, and connective tissue so effectively.

Tumors need that same blood supply to grow. A dormant cluster of cancer cells can't expand past a few millimeters without recruiting vasculature. The mechanism that makes BPC-157 a regenerative powerhouse is the mechanism tumors hijack to grow.

That's the concern. It's mechanistically valid. Anyone running peptides should understand it.

It's also true that there are zero completed randomized controlled trials of BPC-157 in humans. The compound has been used at scale for years based on animal data, mechanism understanding, and clinical experience — not Phase 3 RCTs. That's a real gap.

If the conversation stopped there, Nicola would be on solid ground.

Where the Framing Breaks Down

The episode title is "Peptides, Cancer and the Deadly Habits That Lead to Alzheimer's." The clip economy that drives podcast reach turns that into "neurophysiologist warns BPC-157 could cause cancer."

Nicola's actual written position is materially softer than that hook.

In her own Substack post, she writes: "I'm not saying BPC-157 causes cancer. I'm saying we don't know if it causes cancer, because no one has done the long-term studies to find out."

That's a "we don't know" position. Not a "this is dangerous" position. There's a meaningful difference between those two stances, and the second one is what the audience is walking away with.

More importantly — there's a body of research on this exact question that didn't make it into the episode framing.

The Research That Got Left Out

A peer-reviewed comment in Pharmaceuticals (2025, MDPI / PMC12567428) directly addressed the tumorigenesis hypothesis around BPC-157 and rebutted it based on the available evidence. Quoting the paper directly:

In human melanoma cell lines, BPC-157 "counteracted the effects of VEGF and inhibited cell growth and VEGF signaling via the MAPK kinase pathway." Not stimulated. Inhibited.
In mice, BPC-157 "considerably reduced the number of lung metastases induced by melanoma B-16."
In mice with C26 colon adenocarcinoma, BPC-157 "counteracted tumor cachexia, severe muscle wasting, corrected deranged muscle proliferation and myogenesis, counteracted weight loss, and markedly prolonged survival."
It "significantly counteracted an increase in proinflammatory and procachectic cytokines such as interleukin 6 (IL-6) and tumor necrosis factor (TNF-alpha)."

A separate 2025 narrative review in Current Reviews in Musculoskeletal Medicine — "Regeneration or Risk?" (PMC12446177) — reaches a similar conclusion: "BPC-157 has been shown to inhibit uncontrolled cell proliferation, downregulate VEGF expression, and counteract VEGF-driven tumorigenesis, including suppression of Ki-67 and VEGF pathway activation."

The picture this paints is more interesting than "promotes angiogenesis = feeds tumors." BPC-157 appears to behave context-dependently — promoting healing in damaged tissue while modulating (not blindly stimulating) VEGF in tumor microenvironments. That's a meaningfully different drug profile than the simple narrative suggests.

None of this got airtime.

See What BPC-157 Actually Costs

Before we keep going — if you came here because you've been hearing about BPC-157 and want to see what it actually costs across vetted vendors, Stacked tracks live $/mg pricing across every vendor in our directory with no pay-for-placement.

→ Compare BPC-157 prices across vetted vendors →

Now, back to the story.

The Carcinogenesis Question — Settled, Within the Limits of the Data We Have

There's a clean distinction the episode didn't draw: initiating cancer vs. accelerating existing cancer.

On initiation: there is no credible, peer-reviewed evidence that BPC-157 is a carcinogen. No documented human cancers attributed to it. No animal data showing malignant transformation.

On acceleration of existing cancer: this is where the theoretical concern legitimately sits — but as the research above shows, even this isn't a clean "yes." The compound's behavior in tumor models has been mixed-to-favorable.

The honest framing is:

"BPC-157 doesn't appear to initiate cancer, may have context-dependent effects on existing tumor microenvironments, and lacks long-term human safety data."

That's a very different statement than "BPC-157 could cause cancer."

The Bigger Problem: When Caution Becomes Its Own Risk

Here's the part of this conversation that almost never gets covered when a credentialed expert raises a safety flag on a peptide:

The opportunity cost of avoidance is rarely zero.

If you scare a million people off BPC-157 based on incomplete framing, what do they actually do? Some of them just live with the chronic injury or gut dysfunction. Most of them substitute other interventions. And those substitutes have their own risk profiles — profiles that are better documented than BPC-157's, and not always in ways that favor them.

Chronic NSAID use (the default fallback for tendinopathy and joint pain) has a documented adverse-event burden in the U.S. literature: roughly 100,000 hospitalizations annually attributed to NSAID complications, and a fatality range that depending on methodology runs anywhere from ~3,200 to ~16,500 deaths per year, plus a long-term cancer signal in some cohorts (AJMC review of NSAID-associated adverse events).

Repeated cortisone injections degrade cartilage and weaken tendons over time. The MRI literature on this is consistent.

Untreated gut inflammation drives systemic inflammatory load that downstream literature links to multiple long-term disease processes — including cardiovascular disease and cognitive decline.

Untreated tendon and connective tissue injuries lead to compensation patterns, surgical interventions, and chronic dysfunction.

None of these alternatives get evaluated against BPC-157 in the "is it safe" conversation. They're treated as the invisible default. They shouldn't be.

The honest comparison isn't "BPC-157 vs. doing nothing in a risk-free state." It's "BPC-157 vs. the actual alternatives a person with this problem will use." And in that comparison, the calculus often looks very different than the podcast clip suggests.

The Stacked Position

We're not in the business of telling anyone what to put in their stack. That's between you, your provider, and your bloodwork.

We are in the business of insisting the conversation include the whole picture.

When a credentialed expert raises a real concern, that concern deserves to be taken seriously. Angiogenesis is real. The lack of long-term human data is real. Anyone with active cancer, recent diagnosis, or strong family history should be having a different conversation than someone with a torn rotator cuff and a clean medical history.

But "we don't know enough" is not the same as "it's dangerous." And presenting the second when the data supports the first isn't caution — it's a different framing problem, one that's easy to miss when it comes wrapped in clinical credentials and a measured tone.

The people who lose when peptide conversations get reduced to fear hooks are the same people who would benefit most from accurate information: men and women trying to recover from injury, manage chronic inflammation, or extend their healthspan past the point that conventional medicine cares about.

They deserve the whole story. Mechanism, real risks, real data, real alternatives, real tradeoffs.

That's what this platform exists to deliver — and what our Stacked Score methodology is built around.

Know your stack.

Related Peptides

PeptideKPV PeptideBPC-157 PeptideGHK-Cu PeptideTB-500

Liked this? Get the weekly signal.

New peptide deep dives, vendor score updates, and price-drop alerts. Published weekly. No spam.

For research purposes only. Affiliate links may be included.